NCT00398320 2017-03-01Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine TumorsStanford UniversityPhase 2 Completed40 enrolled 9 charts
NCT00137774 2013-04-09Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine TumorsDana-Farber Cancer InstitutePhase 2 Completed34 enrolled